Posting of 2024 Annual Report and Notice of AGM

About this update from Arecor Therapeutics Plc

Arecor Therapeutics plc ("Arecor" or the "Company")   Posting of Arecor 2024 annual report and notice of AGM   Cambridge, UK, 6 May 2025 : Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, announces that it has today published and posted to shareholders the Annual Report and Accounts for the year ended 31 December 2024 and Notice of the Annual General Meeting ("AGM") which will be held at the offices of Covington & Burling LLP, 22 Bishopsgate, London EC2N 4BQ, on Monday 2 June 2025 at 09.30 a.m. (BST).   The Annual Report and Accounts and notice of AGM are also available to view on, and download from, the Company's website at https://arecor.com/investor-centre/shareholder-information/   -ENDS-   For more information, please contact:   Arecor Therapeutics plc www.arecor.com Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060 Email: [email protected] David Ellam, Chief Financial Officer Tel: +44 (0) 1223 426060 Email: [email protected]   Singer Capital Markets Advisory LLP (NOMAD and Broker) Phil Davies, Sam Butcher Tel: +44 (0) 20 7496 3000   ICR Healthcare Chris Gardner, David Daley, Lindsey Neville Tel: +44 (0) 20 3709 5700 Email: [email protected]     Notes to Editors   About Arecor Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. For further details please see our website, www.arecor.com

View stock analysis, news, and events for Arecor Therapeutics Plc